Literature DB >> 26155406

Deciphering the genetic evolution of T-cell resistance in melanoma.

Antje Sucker1, Annette Paschen1.   

Abstract

T-cell-based immunotherapy of melanoma becomes ineffective when β2m-deficient tumor cells of a human leukocyte antigen (HLA) class I-negative phenotype grow out. We demonstrated that an early-acquired chromosomal deletion and subsequent inactivating gene mutation lead to β2m deficiency, suggesting that melanoma cells can genetically evolve to avoid being recognized by CD8+ T cells.

Entities:  

Keywords:  CD8+ T cells; HLA class I loss; genetic alterations; melanoma; β2m deficiency

Year:  2015        PMID： 26155406      PMCID： PMC4485751          DOI： 10.1080/2162402X.2015.1005510

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

2.  Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Authors:  Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Authors:  Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

4.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

5.  The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.

Authors:  Annette Paschen; Norbert Arens; Antje Sucker; Karin M Greulich-Bode; Ester Fonsatti; Annunziata Gloghini; Sandra Striegel; Nicole Schwinn; Antonino Carbone; Ralf Hildenbrand; Adelheid Cerwenka; Michele Maio; Dirk Schadendorf
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

6.  Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

Authors:  Annette Paschen; Rosa María Méndez; Pilar Jimenez; Antje Sucker; Francisco Ruiz-Cabello; Mingxia Song; Federico Garrido; Dirk Schadendorf
Journal:  Int J Cancer       Date:  2003-03-01       Impact factor: 7.396

7.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

8.  Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Authors:  Hirokazu Matsushita; Matthew D Vesely; Daniel C Koboldt; Charles G Rickert; Ravindra Uppaluri; Vincent J Magrini; Cora D Arthur; J Michael White; Yee-Shiuan Chen; Lauren K Shea; Jasreet Hundal; Michael C Wendl; Ryan Demeter; Todd Wylie; James P Allison; Mark J Smyth; Lloyd J Old; Elaine R Mardis; Robert D Schreiber
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962
  10 in total
  2 in total

1.  Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.

Authors:  Nicholas D Huntington; Gavin P Robertson; Saketh S Dinavahi; Yu-Chi Chen; Kishore Punnath; Arthur Berg; Meenhard Herlyn; Momeneh Foroutan
Journal:  Cancer Immunol Res       Date:  2022-06-03       Impact factor: 12.020

Review 2.  Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.

Authors:  Raquel Tarazona; Esther Duran; Rafael Solana
Journal:  Front Immunol       Date:  2016-01-07       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.